The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies


Background: Although the predictive value of the excision repair cross-complementing group 1 (ERCC1)C118T polymorphism in clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-basedchemotherapy has been evaluated in numerous published studies, the conclusions are conflicting. Therefore, weperformed the present meta-analysis to determine the precise role of the ERCC1 C118T polymorphism in thisclinical situation and help optimize individual chemotherapy. Materials and
Methods: A multiple search strategywas used to identify eligible studies. Pooled odds ratios (ORs) and their 95% confidence intervals (CIs) wereused to estimate objective response and oxaliplatin-induced toxicity, with hazard ratios (HRs) with 95%CIs forprogression-free survival (PFS) and overall survival (OS).
Results: A total of 22 studies including 2,846 CRCpatients were eligible in the analysis. Overall, no significant correlation was found between the ERCC1 C118Tpolymorphism and objective response to oxaliplatin-based chemotherapy, in all patients or in the Asian andCaucasian subgroups. However, the pooled analysis showed that the PFS and OS were significantly shorter inpatients who carried T/T or T/C genotypes of ERCC1 C118T as compared to the C/C genotype. On stratifiedanalysis by ethnicity, the ERCC1 118T allele was associated with a favorable prognosis in Caucasians (PFS,HR=0.58, 95%CI: 0.24-1.44; OS, HR=0.38, 95%CI: 0.22-0.64) but an unfavorable prognosis in Asians (PFS,HR=2.49, 95%CI: 1.87-3.33; OS, HR=2.63, 95%CI: 1.87-3.69) based on a dominant model. In addition, wefailed to find a statistically significant impact of ERCC1 C118T polymorphism on oxaliplatin-induced toxicity.
Conclusions: The ERCC1 C118T polymorphism may have prognostic value in patients with CRC undergoingoxaliplatin-based chemotherapy.